Peptides DB
Research-centric peptide and protocol reference hub

BPC-157 record · updated 17h ago

Healing & recoveryInflammation & immuneGrade B · human evidenceResearch use only
All 14 studiesJump to the evidenceCompare
What is BPC-157 used for?

Body Protective Compound often discussed for soft-tissue repair, GI support, and inflammation modulation.

How it works: Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling

Primarily researched for · Healing & recoveryRoute · Subcutaneous / oral (research use)

Development stage

where BPC-157 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 58 registered trials. It describes the research record, not a recommendation.

Identity
NameBPC-157
Chain length15 amino acids
SequenceGEPPPGKPADDAGLV
Molecular weight1,419.5 Da
FormulaC62H98N16O22
Structure typePeptide
ClassHealing
Research levelPreclinical
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 9941957. The chain length is only shown where the residues account for that mass, so a figure here has been checked against it rather than taken on trust.

Pharmacology
MechanismBody-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling
RouteSubcutaneous / oral (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 28, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular6 / 1 / 2
Highest trial phasePreclinical
Years covered2010–2026
Latest study4d ago
Publication history
20102026
Research funding
1,675 NIH projects · $27.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports26
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
First Case Report of Triple Recurrent Cholangitis of "Coildocholithiasis," Following Hepatic Artery Pseudoaneurysm Embolization.
FindingNot reported in abstract.
Human2023Full text read0.80
Mechanism of Fibrotic Anastomosis Formation in Endoscopic Ultrasound-guided Hepaticogastrostomy Using a Plastic Stent: Insights From an Autopsy Case of Perihilar Cholangiocarcinoma.
FindingNot reported in abstract.
Human2023Full text read0.70
Endoscopic Diagnosis of <i>Necator americanus</i> Infection Presenting With Persistent Iron-Deficiency Anemia: Usefulness of Image-Enhanced Endoscopy and Capsule Endoscopy.
FindingNot reported in abstract.
Human2023Full text read0.80
Time to Confirmed Completion of Bowel Preparation as a Preprocedural Indicator of Colonoscope Insertion Difficulty: A Prospective Observational Study.
FindingEach 30-min increase in time to confirmed completion of bowel preparation was associated with longer cecal intubation time (exp(β), 1.139; 95% CI, 1.065-1.219).
Human2023Full text read0.80
Gastric Metastasis of Uterine Leiomyosarcoma Detected During Surveillance Endoscopy and Resected by Endoscopic Submucosal Dissection After Multiple Metachronous Metastases: A Case Report.
FindingNot reported in abstract.
Human2023Full text read0.80
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
FindingNot reported in abstract.
Animal2026Full text read0.70
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
FindingIC50 value of CIARA-1 = 2.52 mM.
In vitro2026Full text read0.70
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Finding41.6% to 71.1% of samples failed to meet basic quality criteria.
review2020Full text read0.80
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
FindingIC50 for CIARA-1 = 2.52 mM
In vitro2023Full text read0.80
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
FindingNot reported in abstract.
Human2026Full text read0.80
Semantic Scholar search for BPC-157
TakeawayNot reported in abstract.
—2010Title only0.00
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
FindingNot reported in abstract.
review2023Partial text0.60

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching BPC-157 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much BPC-157 is discussed should be drawn from it.

Articles mentioning BPC-157